

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Post-Traumatic Stress Disorder in Patients with Rheumatic Disease during the COVID-19 Outbreak

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049749
Article Type:	Original research
Date Submitted by the Author:	03-Feb-2021
Complete List of Authors:	Wu, Xin; Shanghai Changzheng Hospital Geng, Xuqiang; Shanghai Changzheng Hospital Shang, Zhilei; Second Military Medical University Wang, Zhen; Shanghai Changzheng Hospital Lu, Hongjuan; Shanghai Changzheng Hospital Ma, Haiying; Second Military Medical University Liu, Weizhi; SMMU, Xu, Huji; Shanghai Changzheng Hospital
Keywords:	COVID-19, MENTAL HEALTH, RHEUMATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title page**Title:**

Post-Traumatic Stress Disorder in Patients with Rheumatic Disease during the COVID-19 Outbreak

Authors:

Xin Wu^{1*}, Xuqiang Geng^{1*}, Zhilei Shang^{3,4*}, Zhen Wang, Hongjuan Lu¹, Haiying Ma^{3**}, Weizhi

Liu^{3,4**}, Huji Xu^{1,2**}

* These authors contributed equally as first authors.

**Co-corresponding authors.

Author Affiliations:

¹ Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Naval Medical

University, Shanghai 200003, China

² School of Clinical Medicine, Tsinghua University, Beijing, 100084, China

³ The Emotion & Cognition Lab, Faculty of Psychology and Mental Health, Naval Medical University,

Shanghai, 200433, China

⁴ Lab for Post-traumatic Stress Disorder, Faculty of Psychology and Mental Health, Naval Medical

University, Shanghai, 200433, China

Authors for correspondence:

Professor Huji Xu,

Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Naval Medical

University, 415 Fengyang Road, Shanghai 200003, China. Tel/Fax: +86-21-6351 9841, E-mail:

xuhuji@smmu.edu.cn

Professor Weizhi Liu,

1
2
3
4 Lab for Post-traumatic Stress Disorder, Faculty of Psychology and Mental Health, Naval Medical
5
6 University, 800 Xiangyin Road, Shanghai 200433, China. Tel/Fax: +86-21-81871671, E-mail:
7
8
9 13024141970@163.com
10

11 Professor Haiying Ma,
12

13
14 The Emotion & Cognition Lab, Faculty of Psychology and Mental Health, Naval Medical University,
15
16
17 800 Xiangyin Road, Shanghai 200433, China. Tel/Fax: +86-21-81871671, E-mail:
18
19 haiying199901@163.com
20
21

22 **Shortened title:**
23

24 PTSD in RD Patients during the COVID-19 Outbreak
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: The COVID-19 pandemic is not only a traumatic event, but a collective stressor unfolding over time, causing devastating implications for the mental health. This study aimed to shed light on the mental health status of patients with rheumatic disease (RD) during the massive outbreak of COVID-19 in China, especially the prevalence and severity of post-traumatic stress disorder (PTSD) compared with healthy individuals.

Methods: A total of 486 RD patients and 486 age- and sex-matched healthy individuals were recruited into the study. For each participant, we collected demographic and clinical characteristics data. The PTSD Checklist for DSM-5 (PCL-5) and 4 items from the Pittsburgh Sleep Quality Index (PSQI) were used to investigate the prevalence and severity of PTSD and sleep quality, respectively.

Results: Compared with healthy control subjects (n=486), RD patients (n=486) had a higher prevalence of PTSD (12.1% vs. 4.1%; $p < 0.001$). Higher total scores on the PCL-5 and on all four items from the PSQI ($p \leq 0.001$) were also observed. Female, old age, poor sleep quality, long duration of RD, poor subjective evaluation of the disease and pessimistic subjective perception of the epidemic were identified as risk factors of PTSD in RD patients during the COVID-19 epidemic.

Conclusion: During the COVID-19 outbreak, RD patients presented a higher prevalence and severity of PTSD and showed more sleep disturbances. Our findings confirm the importance of psychological assessment and mental health care out of regular clinical care for RD patients during the pandemic.

Keywords

COVID-19, Mental health, Post-traumatic stress disorder, Sleep disorders, Rheumatic diseases

Strengths and limitations of this study

First, we adopted a case-control study to compare the prevalence and severity of PTSD in patients with rheumatic disease (RD) and healthy controls. Secondly, the sample size of this study was large, and two groups were matched in age and gender, which has high promotion value. Thirdly, this study was carried out during the massive outbreak of COVID-19 in China and compared the different psychological reactions to COVID-19 of RD patients and healthy controls. Finally, the main limitation of this study was a cross-sectional study, which cannot indicate whether the high prevalence and severity of PTSD in RD patients due to the different reactions to the epidemic of COVID-19 or the rheumatic disease.

Introduction

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread throughout the world, causing a pandemic. By Jan 2021, it had spread across 207 countries with more than 99 million confirmed cases and exceeded 2 million deaths worldwide. The outbreak of COVID-19 unleashed public panic and fuelled psychological problems, especially fear, depression, anxiety, stress, irritability, insomnia, confusion, boredom, and stigma associated with quarantine¹. Thereinto, the post-traumatic stress disorder (PTSD) arising from exposure to trauma needs of wide attention urgently². Many patients and medical staff experienced PTSD during the outbreaks of SARS, MERS, and Ebola³⁻⁵. Even ordinary residents in epidemic areas became high-risk populations of PTSD. Several studies revealed that 6-14% of the general population experienced PTSD during the SARS outbreak,⁶ while the PTSD rate during the COVID-19 pandemic has been estimated at 7-32%^{7,8}, a statistic that includes indirect victims of the contagion. Thus, PTSD should be given more focus during the outbreak of COVID-19.

Patients with rheumatic diseases (RDs), such as ankylosing spondylitis (AS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), had a high prevalence of mental health disorders, especially anxiety, depression, and cognitive impairment⁹. The negative impacts of these mental illnesses in the context of RD included increased disease activity, suboptimal treatment adherence, reduced treatment response, and decreased quality of life. Furthermore, due to disease activity, comorbidities, and immunosuppressive therapy, patients with RD might be more susceptible to COVID-19 than the general population¹⁰. They were also more nervous and expressed more hypochondria on account of the many similarities in clinical symptoms between RDs and COVID-19, such as fever, anaemia and elevated C-reactive protein (CRP) levels¹¹. As a result, the psychological problems of RD patients during the

1
2
3
4 COVID-19 epidemic need to be particularly addressed, while few studies have examined so far. This
5
6 study aimed to shed light on the mental health status of RD patients during the COVID-19 epidemic in
7
8
9 China, especially the prevalence and severity of PTSD compared with healthy individuals.
10

11 12 13 14 15 16 17 **Methods**

18 19 **Study design and subjects**

20
21
22 A cross-sectional case-control study was conducted with 490 consecutive RD patients who received
23
24 regular clinical follow-up in the Rheumatology and Immunology Department of Shanghai Changzheng
25
26 Hospital from February to April 2020 which was the worst period of COVID-19 in China, The exclusion
27
28 criteria for the RD patients included (1) patients ≤ 18 years old, (2) patients with hearing or cognitive
29
30 impairment or an inability to fill out the questionnaire, (3) patients who spent more than 30 minutes or
31
32 less than 2 minutes answering the questionnaire, and (4) patients previously diagnosed with PTSD. In
33
34
35 addition, age- and sex-matched healthy individuals were volunteered as controls. They completed the
36
37 same questionnaire online, excluding volunteers under the age of 18 and those who were unable to
38
39 understand and complete the questionnaire or who had been previously diagnosed with RD or PTSD.
40
41
42 This study was approved by the Human Research Ethics Committee of Changzheng Hospital
43
44
45 (2017SL046), and informed consent was obtained from all participants.
46
47
48
49

50 51 **Demographic and clinical characteristics**

52
53 Demographic variables included gender, age, occupation, education level, income, quarantine status, and
54
55 marital status. Clinical variables included clinical diagnosis, disease duration, patient global assessment
56
57 visual analogue scale (PGA-VAS) score, sleep quality and disorders, weekly exercise frequency, and
58
59
60

1
2
3
4 subjective perception of the COVID-19 epidemic. Subjective perception of the COVID-19 epidemic was
5
6 assessed via the following three questions: 1) “How dangerous is COVID-19 to life and health?”; 2)
7
8 “How much does COVID-19 affect life, work or study?”; and 3) “How confident are you in defeating
9
10 COVID-19?”. Responses were given on a five-point Likert scale from 1 (nothing at all) to 5 (highest)¹².
11
12

13 14 **Measurement of PTSD**

15
16 The PTSD checklist for DSM-5 (PCL-5) was used to assess PTSD symptoms¹³. There are 20 items
17
18 including 4 symptom clusters: intrusion symptoms (Criterion B, items 1-5), avoidance symptoms
19
20 (Criterion C, items 6, 7), negative alterations in cognition or emotional symptoms (Criterion D, items 8-
21
22 14), and hyper-arousal symptoms (Criterion E, items 15-20). Each item was scored on a five-point Likert
23
24 scale from 0 (nothing at all) to 4 (extremely), representing the degree to which an individual has been
25
26 bothered by PTSD-related symptoms during the past month. The overall score and the sum of each
27
28 symptom were both investigated. A score of 33 or greater is suggested as a probable diagnosis of PTSD.
29
30
31
32

33
34 The Chinese version of the PCL-5 has psychometric properties that are similar to those of the original
35
36 version and is widely used in trauma-related research and practice¹⁴. The COVID-19 epidemic put the
37
38 Chinese population at risk of a deadly pandemic. According to PCL-5's DSM-5 Life Events List (LEC-
39
40 5)¹⁵, this public health disaster is a traumatic event. Therefore, PCL-5 was used to assess PTSD symptoms.
41
42
43
44

45 46 **Measurement of sleep quality**

47
48 Self-reported sleep quality was measured based on 4 questions extracted from the Pittsburgh Sleep
49
50 Quality Index (PSQI)¹⁶, including “subjective sleep quality”, “unable to fall asleep within 30 minutes”,
51
52 “easily waking up at night or in the early morning” and “sleep time lasting for one month”. Each item
53
54 was scored from 0 to 3, with higher scores indicating more severe sleep disorders.
55
56
57

58 59 **Statistical Analysis**

1
2
3
4 Statistical analysis was performed using IBM SPSS version 21.0. A two-tailed test was used, and $p < 0.05$
5
6 was considered as statistically significant. Descriptive and frequency statistics (mean, [SD] and
7
8 percentages) were used to describe baseline demographic information and clinical information. First,
9
10 descriptive statistics were calculated for the demographic variables, clinical diagnosis data, disease
11
12 duration data, and subjective evaluation scores of the RD patient population. Then, the chi-squared test
13
14 and t test were used to analyse the prevalence of PTSD, the PTSD symptoms and sleep quality of the
15
16 rheumatic group and the control group. Then, one-way analysis of variance (ANOVA) was used to
17
18 analyse the difference in the PCL-5 scores between different disease courses and clinical diagnoses in
19
20 the RD group. Last, hierarchical regression analysis was used to determine the independent variables
21
22 related to PTSD in the RD group.
23
24
25
26
27
28
29
30
31

32 **Results**

33 **Demographic and clinical information of the RD patients**

34
35 A total of 490 RD patients were recruited to complete the survey. Of the 490 respondents, 4 participants
36
37 were removed due to illogical answers (for example, all choices were one or zero). Therefore, 486
38
39 participants were included in this analysis. As illustrated in Table 1, the sample comprised 301 males
40
41 and 185 females with an average age of 40.03 years (SD, 14.70 years). Regarding the diagnosis, there
42
43 were 289 (59.5%) patients with AS, 79 (16.3%) patients with RA, 15 (3.1%) patients with SLE, 10 (2.1%)
44
45 patients with osteoarthritis (OA), 10 (2.1%) patients with osteoporosis (OP), 33 (6.8%) patients with gout,
46
47 10 (2.1%) patients with Sjogren's syndrome (SS), 11 (2.3%) patients with psoriatic arthritis (PsA) and
48
49 33 (6.8%) with other rheumatic diseases. In terms of the classification of the course of their RD, 39 (8.0%)
50
51 patients were diagnosed less than 1 year ago, 205 (42.2%) patients were diagnosed between 1 and 5 years
52
53
54
55
56
57
58
59
60

ago, and 242 (49.8%) patients were diagnosed more than 5 years ago. A total of 292 (60.1%) patients had PGA-VAS scores between 1 and 5, and 194 (39.9%) patients had PGA-VAS scores between 6 and 10. The subjective perception of the COVID-19 epidemic scores (1-5) were as follows: Q1 (2.52±1.18), Q2 (3.26±1.10), and Q3 (4.38±0.81).

The difference of PTSD symptoms and sleep quality between RD patients and healthy controls

The PTSD symptoms and sleep quality of two groups were then analysed (Table 2). The mean PCL-5 score of the patients with RD (18.40 ± 11.47) was significantly higher than that of the healthy controls (11.07 ± 10.04) ($p < 0.001$), with all four criteria rated significantly higher for RD patients than healthy respondents ($p < 0.001$), indicating that all four types of symptoms (intrusion, avoidance, negative changes in cognition or mood, hyper-arousal) are more severe in rheumatic patients. A total of 12.1% (59/486) of RD patients and 4.1% (20/486) of healthy controls scored 33 or higher and met the diagnostic criteria for PTSD. Compared with the number of healthy controls, there were significantly more RD patients who fulfilled the diagnostic criteria for PTSD ($p < 0.001$).

In terms of the diagnostic classification, although there were no significant differences between the subgroups, the Criterion B (intrusion symptoms) scores of the SLE patients were significantly higher than those of the RA patients ($p < 0.05$) (see Figure 1).

Regarding sleep quality and disorders, the scores of the four items from the PSQI (“subjective sleep quality”, “unable to fall asleep within 30 minutes”, “easily waking up at night or in the early morning” and “sleep time”) were significantly higher in the RD patients than the healthy control group. The results indicated that during the COVID-19 pandemic, the prevalence and severity of PTSD were significantly higher in RD patients than healthy controls, and the sleep quality of PD patients was also worse.

Factors related to PTSD in RD patients

1
2
3
4 With the PCL-5 score as the dependent variable and related variables as independent variables, the results
5
6 of the hierarchical regression analysis were listed in Table 3.
7

8
9 In the first step, the demographic variables included accounted for 2.3% of the variance in PTSD
10
11 symptoms. In the second step, the clinical characteristics of the RD patients were included in the model,
12
13 and the subjective assessment of the disease had a significant effect on the PCL-5 scores. For the course
14
15 of the RD, we defined “1-5 years” as a dummy variable and found that the PCL-5 scores in the “<1 year”
16
17 group were significantly higher than those in the reference group ($p<0.05$) (see Figure 2). These features
18
19 related to RD accounted for 5.8% of the unique variance. In the third step, two questions on the subjective
20
21 perception of the COVID-19 epidemic (Q2 and Q3) were also statistically significant ($p<0.001$),
22
23 accounting for 7.9% of the difference in the results. The sleep quality score was added to the final step
24
25 of the hierarchical regression, thereby increasing the variance by 5.8%.
26
27
28
29
30
31

32 In the final model, gender ($\beta=0.147$, $p=0.001$), subjective assessment of the disease ($\beta=0.112$, $p=0.014$),
33
34 and Q2 regarding the subjective perception of the COVID-19 epidemic ($\beta=0.110$, $p=0.046$) were
35
36 positively correlated with the severity of PTSD symptoms, whereas age ($\beta=-0.155$, $p=0.001$) and Q3 ($\beta=-$
37
38 0.194 , $p<0.001$) were negatively correlated with PTSD symptoms. In summary, the total variation
39
40 contribution of these variables to the PCL-5 score was significant ($R^2=21.7\%$, $F=10.899$, $p<0.001$).
41
42
43
44
45
46
47

48 Discussion

49
50 Although the disease status and the treatment of RD patients have been widespread concerned¹⁷, almost
51
52 nothing is known with certainty about the psychological impact of the COVID-19 pandemic on RD
53
54 patients. In fact, RD patients are more susceptible to mental disorders during this COVID-19 outbreak.
55
56 It was demonstrated that RD patients suffered more from PTSD and sleep disorders than healthy controls
57
58
59
60

1
2
3
4 and had significantly higher PCL-5 scores and individual criteria scores. That is to say, RD patients have
5
6 higher odds of developing PTSD in the context of the COVID-19 pandemic. Our findings confirm the
7
8 importance of psychological assessment and care for RD patients during the pandemic.
9

10
11 Fears had risen in RD patients because of the higher risks of COVID-19 infection¹⁰, as a result of high
12
13 similarity in clinical symptoms between RDs and COVID-19. A significant bidirectional relationship
14
15 between autoimmune diseases and PTSD was observed¹⁸. That is, PTSD patients were prone to
16
17 comorbidity with autoimmune disease¹⁹, and vice versa²⁰. It was hypothesised that psychoneuroimmunity
18
19 (PNI) imbalance was the leading cause. PTSD was characterized by abnormal activation of the
20
21 hypothalamus-pituitary-adrenal axis (HPA axis), which was thought to communicate with the immune
22
23 system in a two-way manner²¹. On the one hand, it had been suggested that dysregulation of the HPA
24
25 axis will exacerbate systemic inflammation, which may be involved in the pathogenesis of chronic
26
27 inflammatory autoimmune diseases such as SLE and RA²². On the other hand, the chronic inflammatory
28
29 state caused by RD will aggravate the dysregulation of the HPA axis, which will further disturb the
30
31 physiological stress response of RD patients and make them more susceptible to PTSD⁹. Circulating
32
33 cytokines may also be involved in making RD patients more susceptible to PTSD. Some recent reports
34
35 demonstrated that serum interleukin-1 (IL-1), IL-6, tumour necrosis factor (TNF) and interferon (IFN)-
36
37 γ levels were increased in patients with PTSD²³. These factors were also involved in the pathogenesis of
38
39 RDs, such as RA and SLE²⁴.
40
41
42
43
44
45
46
47
48
49

50 As expected, the sleep of RD patients was disturbed, in accordance with the results of previous studies.
51
52 Psychosocial variables, steroid use, and chronic pain were possible psychobiological factors²⁵. Sleep
53
54 disorders also seemed to be a core feature of PTSD²⁶, suggesting that PTSD symptoms may be worse in
55
56 RD patients.
57
58
59
60

1
2
3
4 Although no significant difference was observed in the PCL-5 scores among different diagnosis
5
6 subgroups, all standard scores of patients with SLE and OP tended to be higher. SLE patients may be
7
8 more stressed due to severe systemic involvement and drug shortages. They were concerned that
9
10 chloroquine will become a specific drug for COVID-19²⁷, resulting in a higher Criterion B (intrusion
11
12 symptom) score for SLE patients than for other RA patients. Consistent with previous findings, patients
13
14 with OP may be more sensitive to PTSD due to age²⁸. However, future studies with more samples should
15
16 be carried out to verify and expand such results.
17
18
19
20
21

22 It is not lightweight to explore the psychological impact of COVID-19 in different groups of RD patients.
23
24 Consequently, female, old age, poor sleep quality, long duration of RD, poor subjective evaluation of the
25
26 disease and a pessimistic subjective perception of the epidemic were identified as risk factors for PTSD
27
28 in RD patients during the COVID-19 epidemic.
29
30
31

32 In the current study, females were at higher risk to develop PTSD, in line with previous studies that
33
34 explored predictors of PTSD during the COVID-19 epidemic.⁷ It has been shown that females usually
35
36 tended to present depression, physical anxiety sensitivity, and helplessness which were all proven to be
37
38 PTSD-related risk factors²⁹. As expected, age and sleep quality were predictive factors of PTSD and have
39
40 been widely explored in relevant studies^{30,31}.
41
42
43
44

45 It is important to note that long duration and poor subjective assessment of RD determined the risk of
46
47 PTSD to a certain extent. Patients with longer disease course were more likely to suffer from
48
49 psychological problems caused by chronic stress³². Among people with different disease durations, those
50
51 in “1-5 years” group had significantly higher PTSD levels than those in “<1 year” group. However,
52
53 inconsistent with the hypothesis, the difference between the “1-5 years” and “>5 years” group was not
54
55 significant. One possible reason is that patients who were diagnosed as more than 5 year ago have adapted
56
57
58
59
60

1
2
3
4 to their disease and have even become more resilient to other health-related stressors. Chronic pain
5
6 usually determines the subjective assessment of the disease in RD patients, which is usually complicated
7
8 by PTSD³³. Obviously, during the pandemic of a life-threatening infectious disease, patients with a long
9
10 disease duration and chronic pain should be regarded as at risk of PTSD.
11

12
13
14 Regarding the subjective perception of the epidemic, the symptoms of PTSD caused by pessimism and
15
16 fear were more severe, which was consistent with research on the psychological impact of SARS¹².
17
18 Media reports emphasized that COVID-19 is a unique threat, which further exacerbates the possibility
19
20 of panic, stress hysteria and fear. Fear is an adaptive response that triggers defensive behaviours to protect
21
22 ourselves. If the fear is not managed properly, PTSD will develop³⁴. Thus, applying psychological
23
24 interventions to reduce pandemic fears and instilling emotional adaptability during the COVID-19
25
26 pandemic may help prevent the development of PTSD.
27
28
29
30

31
32 Currently, several limitations are worth considering. First, this study lacked research data on the
33
34 prevalence of PTSD before the epidemic in both RD patients and controls. As a result, it is difficult to
35
36 determine whether the high prevalence of PTSD in the RD group is due to COVID-19. In addition, to
37
38 guarantee a reliable subgroup analysis, larger samples are warranted in the future.
39
40
41
42
43
44

45 **Conclusion**

46
47
48 In the context of COVID-19, the present study will provide references not only rheumatologically but
49
50 also psychologically. It is suggested that, compared to healthy controls, RD patients present a higher
51
52 prevalence and severity of PTSD and more sleep disturbances. Under such future life-threatening
53
54 infectious epidemics, as regular clinical care, the importance of mental health in RD patients is nothing
55
56 to sneeze at.
57
58
59
60

Contributorship statement

XW, XG, ZS contributed to the writing of this article and the statistical analysis of this article, who are co-first authors, HM, WL and HX led the whole study, including putting forward this study, carrying out the study, and was the co-corresponding author. ZW and HL contributed to perform the investigation and collection of all data and part of the statistical analysis of this article.

Competing interests

The authors declare that they have no conflicts of interest.

Funding

This work was supported by grants from the National Natural Science Foundation of China (31770988 to X.W., 32071086 to W.L., and 31821003 to H.X.); China Ministry of Science and Technology (2018AAA0100300 to H.X.). Shanghai Municipal Key Clinical Specialty Fund (shslczdzk02602 to H.X.). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Data sharing statement

Data can be provided after the Article is published through the email address of the corresponding authors for communication. The corresponding authors have the right to decide whether to share the data or not based on the research objectives and plan provided. With the permission of the corresponding authors, we can provide participant data without names and identifiers.

References

1. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet* 2020; 395(10227): 912-20. [https://doi.org/10.1016/S0140-6736\(20\)30460-8](https://doi.org/10.1016/S0140-6736(20)30460-8).
2. Duteil F, Mondillon L, Navel V. PTSD as the second tsunami of the SARS-Cov2 pandemic. *Psychological medicine* 2020; 24: 1-2. <https://doi.org/10.1017/S0033291720001336>.
3. Wu KK, Chan SK, Ma TM. Posttraumatic stress after SARS. *Emerging infectious diseases* 2005; 11(8): 1297-300. <http://dx.doi.org/10.3201/eid1108.041083>
4. Lee SM, Kang WS, Cho AR, Kim T, Park JK. Psychological impact of the 2015 MERS outbreak on hospital workers and quarantined hemodialysis patients. *Comprehensive psychiatry* 2018; 87: 123-7. <https://doi.org/10.1016/j.comppsy.2018.10.003>.
5. Reardon S. Ebola's mental-health wounds linger in Africa. *Nature* 2015; 519(7541): 13-4. <https://doi.org/10.1038/519013a>.
6. Lee TM, Chi I, Chung LW, Chou KL. Ageing and psychological response during the post-SARS period. *Aging & mental health* 2006; 10(3): 303-11. <https://doi.org/10.1080/13607860600638545>.
7. Liu N, Zhang F, Wei C, et al. Prevalence and predictors of PTSS during COVID-19 outbreak in China hardest-hit areas: Gender differences matter. *Psychiatry research* 2020; 287: 112921. <https://doi.org/10.1016/j.psychres.2020.112921>.
8. Liu CH, Zhang E, Wong GTF, Hyun S, Hahm HC. Factors associated with depression, anxiety, and PTSD symptomatology during the COVID-19 pandemic: Clinical implications for U.S. young adult mental health. *Psychiatry research* 2020; 290: 113172. <https://doi.org/10.1016/j.psychres.2020.113172>.

- 1
2
3
4 9. De Brouwer SJ, Kraaimaat FW, Sweep FC, et al. Experimental stress in inflammatory rheumatic
5
6 diseases: a review of psychophysiological stress responses. *Arthritis research & therapy* 2010; 12(3):
7
8 R89. <https://doi.org/10.1186/ar3016>.
9
10
- 11 10. Zhong J, Shen G, Yang H, et al. COVID-19 in patients with rheumatic disease in Hubei province,
12
13 China: a multicentre retrospective observational study. *The Lancet Rheumatology* 2020; 2(9): e557-e64.
14
15 [https://doi.org/10.1016/S2665-9913\(20\)30227-7](https://doi.org/10.1016/S2665-9913(20)30227-7).
16
17
- 18 11. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists' perspective on coronavirus
19
20 disease 19 (COVID-19) and potential therapeutic targets. *Clinical rheumatology* 2020; 39(7): 2055-62.
21
22 <https://doi.org/10.1007/s10067-020-05073-9>.
23
24
- 25 12. Wu P, Fang Y, Guan Z, et al. The psychological impact of the SARS epidemic on hospital
26
27 employees in China: exposure, risk perception, and altruistic acceptance of risk. *Canadian journal of*
28
29 *psychiatry* 2009; 54(5): 302-11. <https://doi.org/10.1177/070674370905400504>.
30
31
32
- 33 13. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder
34
35 Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. *Journal of traumatic*
36
37 *stress* 2015; 28(6): 489-98. <https://doi.org/10.1002/jts.22059>.
38
39
- 40 14. Liu P, Wang L, Cao C, et al. The underlying dimensions of DSM-5 posttraumatic stress disorder
41
42 symptoms in an epidemiological sample of Chinese earthquake survivors. *Journal of anxiety disorders*
43
44 2014; 28(4): 345-51. <https://doi.org/10.1016/j.janxdis.2014.03.008>.
45
46
47
- 48 15. Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The PTSD Checklist for
49
50 DSM-5 (PCL-5) – LEC-5 and Extended Criterion A [Measurement instrument]. 2013;
51
52 https://www.ptsd.va.gov/professional/assessment/documents/PCL-5_LEC_criterionA.pdf. Accessed
53
54
55
56
57
58 February 2, 2020.
59
60

- 1
2
3
4 16. Mollayeva T, Thurairajah P, Burton K, Mollayeva S, Shapiro CM, Colantonio A. The Pittsburgh
5
6 sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A
7
8 systematic review and meta-analysis. *Sleep medicine reviews* 2016; 25: 52-73.
9
10 <https://doi.org/10.1016/j.smr.2015.01.009>.
11
12
13
14 17. Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the
15
16 management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. *Annals of the*
17
18 *rheumatic diseases* 2020; 79(7): 851-8. <http://dx.doi.org/10.1136/annrheumdis-2020-217877>.
19
20
21
22 18. Sumner JA, Nishimi KM, Koenen KC, Roberts AL, Kubzansky LD. Posttraumatic Stress Disorder
23
24 and Inflammation: Untangling Issues of Bidirectionality. *Biological psychiatry* 2020; 87(10): 885-97.
25
26 <https://doi.org/10.1016/j.biopsych.2019.11.005>.
27
28
29
30 19. Benros ME. Posttraumatic stress disorder and autoimmune diseases. *Biological psychiatry* 2015;
31
32 77(4): 312-3. <https://doi.org/10.1016/j.biopsych.2014.12.006>.
33
34
35 20. Song H, Fang F, Tomasson G, et al. Association of Stress-Related Disorders With Subsequent
36
37 Autoimmune Disease. *JAMA* 2018; 319(23): 2388-400. <https://doi.org/10.1001/jama.2018.7028>.
38
39
40 21. Somvanshi PR, Mellon SH, Yehuda R, et al. Role of enhanced glucocorticoid receptor sensitivity
41
42 in inflammation in PTSD: Insights from computational model for circadian-neuroendocrine-immune
43
44 interactions. *Am J Physiol Endocrinol Metab* 2020; 319(1): E48-E66.
45
46 <https://doi.org/10.1152/ajpendo.00398.2019>.
47
48
49
50 22. Evers AW, Verhoeven EW, Van Middendorp H, et al. Does stress affect the joints? Daily stressors,
51
52 stress vulnerability, immune and HPA axis activity, and short-term disease and symptom fluctuations in
53
54 rheumatoid arthritis. *Annals of the rheumatic diseases* 2014; 73(9): 1683-8.
55
56 <https://doi.org/10.1136/annrheumdis-2012-203143>.
57
58
59
60

- 1
2
3
4 23. Passos IC, Vasconcelos-Moreno MP, Costa LG, et al. Inflammatory markers in post-traumatic
5
6 stress disorder: a systematic review, meta-analysis, and meta-regression. *The lancet Psychiatry* 2015;
7
8 2(11): 1002-12. [https://doi.org/10.1016/S2215-0366\(15\)00309-0](https://doi.org/10.1016/S2215-0366(15)00309-0).
9
10
11 24. Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic
12
13 diseases - evidence based analysis. *Autoimmunity reviews* 2019; 18(1): 93-106.
14
15 <https://doi.org/10.1016/j.autrev.2018.08.003>.
16
17
18 25. Sangle SR, Tench CM, D'Cruz DP. Autoimmune rheumatic disease and sleep: a review. *Current*
19
20 *opinion in pulmonary medicine* 2015; 21(6): 553-6. <https://doi.org/10.1097/MCP.0000000000000215>.
21
22
23 26. Spoomaker VI, Montgomery P. Disturbed sleep in post-traumatic stress disorder: secondary
24
25 symptom or core feature? *Sleep medicine reviews* 2008; 12(3): 169-84.
26
27 <https://doi.org/10.1016/j.smr.2007.08.008>.
28
29
30 27. Peschken CA. Possible Consequences of a Shortage of Hydroxychloroquine for Patients with
31
32 Systemic Lupus Erythematosus amid the COVID-19 Pandemic. *The Journal of rheumatology* 2020;
33
34 47(6): 787-90. <https://doi.org/10.3899/jrheum.200395>.
35
36
37 28. Cook JM, Simiola V. Trauma and Aging. *Current psychiatry reports* 2018; 20(10): 93.
38
39 <https://doi.org/10.1007/s11920-018-0943-6>.
40
41
42 29. Li SH, Graham BM. Why are women so vulnerable to anxiety, trauma-related and stress-related
43
44 disorders? The potential role of sex hormones. *The lancet Psychiatry* 2017; 4(1): 73-82.
45
46 [https://doi.org/10.1016/S2215-0366\(16\)30358-3](https://doi.org/10.1016/S2215-0366(16)30358-3).
47
48
49 30. Sommer JL, Reynolds K, El-Gabalawy R, et al. Associations between physical health conditions
50
51 and posttraumatic stress disorder according to age. *Aging & mental health* 2019: 1-9.
52
53 <https://doi.org/10.1080/13607863.2019.1693969>.
54
55
56
57
58
59
60

- 1
2
3
4 31. Richards A, Kanady J, Neylan T. Sleep disturbance in PTSD and other anxiety-related disorders:
5
6 an updated review of clinical features, physiological characteristics, and psychological and
7
8 neurobiological mechanisms. *Neuropsychopharmacol.* 2020; 45(1): 55-73.
9
10 <https://doi.org/10.1038/s41386-019-0486-5>.
11
12
13
14 32. Maeng LY, Milad MR. Post-Traumatic Stress Disorder: The Relationship Between the Fear
15
16 Response and Chronic Stress. *Chronic stress* (Thousand Oaks, Calif) 2017; 1: 2470547017713297.
17
18 <https://doi.org/10.1177/2470547017713297>.
19
20
21
22 33. Kind S, Otis JD. The Interaction Between Chronic Pain and PTSD. *Current pain and headache*
23
24 reports 2019; 23(12): 91. <https://doi.org/10.1007/s11916-019-0828-3>.
25
26
27 34. Morey R, Haswell C, Stjepanović D, Dunsmoor J, LaBar K. Neural correlates of conceptual-level
28
29 fear generalization in posttraumatic stress disorder. *Neuropsychopharmacol.* 2020; 45(8): 1380-9.
30
31 <https://doi.org/10.1038/s41386-020-0661-8>.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

	RD patients	
	N	%
Age		
18-34	223	45.9
35-60	203	41.8
>60	60	12.3
Gender		
Male	301	61.9
Female	185	38.1
Clinical diagnosis		
Rheumatoid arthritis, RA	79	16.3
Ankylosing spondylitis, AS	289	59.5
Systemic lupus erythematosus, SLE	15	3.1
Osteoarthritis, OA	10	2.1
Osteoporosis, OP	10	2.1
Gout	33	6.8
Sjogren's syndrome, SS	10	2.1
Psoriatic arthritis, PsA	11	2.3
Other	29	6.0
Duration of disease		
<1 year	39	8.0

1-5 years	205	42.2
>5 years	242	49.8
PGA-VAS scores		
1-5	292	60.1
6-10	194	39.9
Perception of the COVID-19 epidemic situation	MEAN	SD
Q1: How dangerous is COVID-19 to life and health?	2.52	1.18
Q2: How much does COVID-19 affect life, work or study?	3.26	1.10
Q3: How confident are you in defeating COVID-19?	4.38	0.81

Table 1: Demographic information and clinical information for all the RD patients

Note: RD=rheumatic diseases. PGA-VAS scores=Patient Global Assessment Visual Analogue Scale scores.

	RD patients		Control		Chi-square/t	p-value
	Mean/N	SD/%	Mean/N	SD/%		
Total	486	100.00	486	100.00		
Age						
18-34	223	45.90	213	43.88	3.418	0.181
35-60	203	41.80	227	46.71		
>60	60	12.30	46	9.50		
Gender						
Male	301	61.90	302	62.14	0.004	0.947
Female	185	38.10	184	37.90		
PCL-5 Scores						
Total scores	18.40	11.47	11.07	10.00	-10.601	<0.001

For peer review only

1							
2							
3							
4							
5	Criterion B	4.86	3.40	3.22	3.34	-7.577	<0.001
6							
7							
8	Criterion C	2.21	1.97	0.89	1.43	-11.978	<0.001
9							
10							
11	Criterion D	6.20	4.59	3.58	3.94	-7.617	<0.001
12							
13							
14	Criterion E	5.12	3.66	3.58	3.44	-10.601	<0.001
15							
16	Sleep quality						
17							
18							
19	Subjective sleep quality	1.19	0.77	0.78	0.70	-8.424	<0.001
20							
21							
22	Difficulty falling asleep	1.07	1.09	0.51	0.88	-8.782	<0.001
23							
24							
25	Frequent nocturnal or early morning awakening	1.41	1.16	0.82	1.00	-8.269	<0.001
26							
27							
28	Sleep duration	0.95	0.85	0.77	0.84	-3.217	0.001

Table 2: Group differences in demographic information, PCL-5 scores and sleep quality between the RD patient group and the control group

Note: RD=rheumatic diseases. PCL-5=PTSD checklist for DSM-5.

/bmjopen-2021-049749 on 30 March 2022. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

Variables	PCL-5 score				R Square	R Square Change	F	p-value
	B	β	t	p-value				
Step 1								
Age	-0.064	-0.081	-1.762	0.079	0.023	0.023	5.576	0.004
Female vs. Male	3.452	0.146	3.166	0.002				
Step 2								
Age	-0.100	-0.127	-2.719	0.007	0.080	0.058	8.381	<0.001
Female vs. Male	4.253	0.180	3.940	0.000				
Duration of disease <1 year vs. 1-5 years	-4.339	-0.103	-2.243	0.025				
Duration of disease >5 years vs. 1-5 years	0.170	0.007	0.156	0.876				
PGA-VAS scores	1.055	0.210	4.612	<0.001				

Step 3

1									
2									
3									
4									
5									
6	Age	-0.088	-0.112	-2.491	0.013	0.159	0.079	11.260	<0.001
7									
8	Female vs. Male	3.797	0.161	3.579	<0.001				
9									
10	Duration of disease <1 year vs. 1-5 years	-3.847	-0.091	-2.061	0.040				
11									
12	Duration of disease >5 years vs. 1-5 years	0.182	0.008	0.174	0.862				
13									
14	PGA-VAS scores	0.905	0.180	4.014	<0.001				
15									
16	Q1: How dangerous is COVID-19 to life and health?	0.457	0.047	0.964	0.336				
17									
18	Q2: How much does COVID-19 affect life, work or study?	1.816	0.175	3.544	<0.001				
19									
20	Q3: How confident are you in defeating COVID-19?	-3.086	-0.217	-4.970	<0.001				
21									
22									
23									
24									
25									
26									
27	Step 4								
28									
29	Age	-0.121	-0.155	-3.412	0.001	0.217	0.058	10.899	<0.001
30									
31	Female vs. Male	3.471	0.147	3.323	0.001				
32									
33	Duration of disease <1 year vs. 1-5 years	-2.351	-0.056	-1.286	0.199				
34									
35									
36									
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									

Duration of disease >5 years vs. 1-5 years	0.556	0.024	0.546	0.586
PGA-VAS scores	0.561	0.112	2.473	0.014
Q1: How dangerous is COVID-19 to life and health?	0.520	0.053	1.130	0.259
Q2: How much does COVID-19 affect life, work or study?	1.331	0.128	2.642	0.009
Q3: How confident are you in defeating COVID-19?	-2.754	-0.194	-4.545	<0.001
Subjective sleep quality	1.627	0.110	1.999	0.046
Difficulty falling asleep	0.954	0.090	1.678	0.094
Frequent nocturnal or early morning awakening	0.715	0.072	1.401	0.162
Sleep duration	0.878	0.065	1.371	0.171

Table 3: Regression analyses with the PCL-5 score as the dependent variable in all RD patients (n=486)

Note: B =unstandardized beta; β =standardized regression weight. The duration of disease was transformed into two dummy variables (<1 year vs. 1-5 years, >5 years vs. 1-5 years), with 1-5 years as the reference group.

Figures




Figure 1: Group differences in all the PCL-5 criteria between the different subgroups of RD

Note: * p-value<0.05. PCL-5=PTSD checklist for DSM-5. All 4 criteria (B, C, D, E) are components of the PCL-5.




Figure 2: Differences in the PCL-5 scores between different disease duration groups

Note: * p-value < 0.05. The duration of disease was transformed into three groups (< 1 year, 1-5 years, > 5 years).

Figure legends

Figure 1: Group differences in all the PCL-5 criteria between the different subgroups of RD

Note: * p-value<0.05. PCL-5=PTSD checklist for DSM-5. All 4 criteria (B, C, D, E) are components of the PCL-5.

Figure 2: Differences in the PCL-5 scores between different disease duration groups

Note: * p-value<0.05. The duration of disease was transformed into three groups (< 1 year, 1-5 years, > 5 years).

BMJ Open

Post-Traumatic Stress Disorder in Patients with Rheumatic Disease during the COVID-19 Outbreak: a cross-sectional case-control study in China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049749.R1
Article Type:	Original research
Date Submitted by the Author:	30-Oct-2021
Complete List of Authors:	Wu, Xin; Shanghai Changzheng Hospital Geng, Xuqiang; Shanghai Changzheng Hospital Shang, Zhilei; Naval Medical University, Faculty of Psychology and Mental Health Wang, Zhen; Shanghai Changzheng Hospital Lu, Hongjuan; Shanghai Changzheng Hospital Ma, Haiying; Naval Medical University Liu, Weizhi; Naval Medical University, Faculty of Psychology and Mental Health Xu, Huji; Shanghai Changzheng Hospital
Primary Subject Heading:	Rheumatology
Secondary Subject Heading:	Mental health, Rheumatology
Keywords:	COVID-19, MENTAL HEALTH, RHEUMATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title page**Title:**

Post-Traumatic Stress Disorder in Patients with Rheumatic Disease during the COVID-19 Outbreak: a cross-sectional case-control study in China

Authors:

Xin Wu^{1*}, Xuqiang Geng^{1*}, Zhilei Shang^{3,4*}, Zhen Wang, Hongjuan Lu¹, Haiying Ma^{3**}, Weizhi Liu^{3,4**}, Huji Xu^{1,2**}

* These authors contributed equally as first authors.

**Co-corresponding authors.

Author Affiliations:

¹ Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200003, China

² School of Clinical Medicine, Tsinghua University, Beijing, 100084, China

³ The Emotion & Cognition Lab, Faculty of Psychology and Mental Health, Naval Medical University, Shanghai, 200433, China

⁴ Lab for Post-traumatic Stress Disorder, Faculty of Psychology and Mental Health, Naval Medical University, Shanghai, 200433, China

Authors for correspondence:

Professor Huji Xu,

Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Naval Medical

University, 415 Fengyang Road, Shanghai 200003, China. Tel/Fax: +86-21-6351 9841, E-mail:

xuhuji@smmu.edu.cn

1
2
3
4 Professor Weizhi Liu,
5

6 Lab for Post-traumatic Stress Disorder, Faculty of Psychology and Mental Health, Naval Medical
7
8
9 University, 800 Xiangyin Road, Shanghai 200433, China. Tel/Fax: +86-21-81871671, E-mail:
10
11
12 13024141970@163.com
13

14 Professor Haiying Ma,
15

16
17 The Emotion & Cognition Lab, Faculty of Psychology and Mental Health, Naval Medical University,
18
19 800 Xiangyin Road, Shanghai 200433, China. Tel/Fax: +86-21-81871671, E-mail:
20
21
22 haiying199901@163.com
23
24

25 **Shortened title:**

26
27 PTSD in RD Patients during the COVID-19 Outbreak
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: The COVID-19 pandemic is not only a traumatic event, but a collective stressor unfolding over time, causing devastating implications for the mental health. This study aimed to shed light on the mental health status of patients with rheumatic disease (RD) during the massive outbreak of COVID-19 in China, especially the prevalence and severity of post-traumatic stress disorder (PTSD) compared with healthy individuals.

Methods: A total of 486 RD patients and 486 age- and sex-matched healthy individuals were recruited into the study. For each participant, we collected demographic and clinical characteristics data. The PTSD Checklist for DSM-5 (PCL-5) and 4 items from the Pittsburgh Sleep Quality Index (PSQI) were used to investigate the prevalence and severity of PTSD and sleep quality, respectively.

Results: Compared with healthy control subjects (n=486), RD patients (n=486) had a higher prevalence of PTSD (12.1% vs. 4.1%; $p < 0.001$). Higher total scores on the PCL-5 and on all four items from the PSQI ($p \leq 0.001$) were also observed. Female, old age, poor sleep quality, long duration of RD, poor subjective evaluation of the disease and pessimistic subjective perception of the epidemic were identified as risk factors of PTSD in RD patients during the COVID-19 epidemic.

Conclusion: During the COVID-19 outbreak, RD patients presented a higher prevalence and severity of PTSD and showed more sleep disturbances. Our findings confirm the importance of psychological assessment and mental health care out of regular clinical care for RD patients during the pandemic.

Strengths and limitations of this study

► This is the first case-control study to explore the prevalence of post-traumatic stress disorder (PTSD) in patients with rheumatic disease (RD) and general Chinese residents during the massive outbreak of

1
2
3
4 COVID-19 in China.

5
6 ▶ This study is one of the first to compare the different psychological reactions to COVID-19 of RD
7
8 patients and healthy controls.

9
10
11 ▶ This study is a cross-sectional study, which limited to indicate whether the high prevalence and
12
13 severity of PTSD in RD patients due to the different reactions to the epidemic of COVID-19 or the
14
15 rheumatic disease.

16
17
18 ▶ Findings relied on a self-reported survey which may question the authenticity of responses and give
19
20 consideration to social desirability bias.

21
22
23 ▶ To guarantee a reliable subgroup analysis, larger samples are warranted in the future.
24
25
26
27
28

29 30 **Keywords**

31
32 COVID-19, Mental health, Post-traumatic stress disorder, Sleep disorders, Rheumatic diseases
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread throughout the world, causing a pandemic. By Jan 2021, it had spread across 207 countries with more than 99 million confirmed cases and exceeded 2 million deaths worldwide. The outbreak of COVID-19 unleashed public panic and fuelled psychological problems, especially fear, depression, anxiety, stress, irritability, insomnia, confusion, boredom, and stigma associated with quarantine.¹ Thereinto, the post-traumatic stress disorder (PTSD) arising from exposure to trauma needs of wide attention urgently.² Many patients and medical staff experienced PTSD during the outbreaks of SARS, MERS, Ebola and COVID-19.³⁻⁷ Even ordinary residents in epidemic areas became high-risk populations of PTSD. Several studies revealed that 6-14% of the general population experienced PTSD during the SARS outbreak,⁸ while the PTSD rate during the COVID-19 pandemic ranged at 4-35%,^{9,10} a statistic that includes indirect victims of the contagion. Thus, PTSD should be given more focus during the outbreak of COVID-19.

Patients with rheumatic diseases (RDs), such as ankylosing spondylitis (AS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), had a high prevalence of mental health disorders, especially anxiety, depression, and cognitive impairment.^{11,12} The negative impacts of these mental illnesses in the context of RD included increased disease activity, suboptimal treatment adherence, reduced treatment response, and decreased quality of life. Furthermore, due to disease activity, comorbidities, and immunosuppressive therapy, patients with RD might be more susceptible to COVID-19 than the general population.¹³ They were more nervous and suffering from hypochondria on account of the many similarities in clinical symptoms between RDs and COVID-19, such as fever, anaemia and elevated C-reactive protein (CRP) levels.¹⁴ As a result, the psychological problems of RD patients during the COVID-19 epidemic need to be particularly addressed, while few studies have examined so far. This

1
2
3
4 study aimed to shed light on the mental health status of RD patients during the COVID-19 epidemic in
5
6 China, especially the prevalence and severity of PTSD compared with healthy individuals.
7
8
9
10
11
12
13

14 **Methods**

15 **Study design and subjects**

16
17
18
19 According to previous studies, the PTSD rate of the general Chinese residents during the COVID-19
20
21 pandemic has been estimated at 4.6-7.4%.^{9 15} It was revealed that 12-18% of patients with ankylosing
22
23 spondylitis (AS) and rheumatoid arthritis (RA) presented PTSD,^{16 17} which were the main components
24
25 of our recruitments, although lacking large-scale epidemiological data. We estimated the sample size
26
27 with a 6% prevalence of PTSD in the general population and a 12% prevalence of rheumatic patients.
28
29 By calculation, the minimum sample size was 353. A cross-sectional case-control study was conducted
30
31 with 490 consecutive RD patients who received regular clinical follow-up in the Rheumatology and
32
33 Immunology Department of Shanghai Changzheng Hospital from February to April 2020 which was the
34
35 worst period of COVID-19 in China. All patients completed standardized questionnaire under the
36
37 guidance of physicians, which took about 10 to 15 minutes and included demographic and clinical
38
39 characteristics, measurements of PTSD and sleep quality. The exclusion criteria for the RD patients
40
41 included (1) patients ≤ 18 years old, (2) patients with hearing or cognitive impairment or an inability to
42
43 fill out the questionnaire, (3) patients who spent more than 30 minutes or less than 2 minutes answering
44
45 the questionnaire, and (4) patients previously diagnosed with PTSD. At the same time, we also recruited
46
47 healthy volunteers from the community in Shanghai who had similar demographic characteristics of
48
49 patients with RD as comparison group. All the participants completed the same questionnaire online. We
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 also excluded volunteers under the age of 18 and those who had been previously diagnosed with RD or
5
6 other complex disease. Finally, 486 age- and sex-matched healthy individuals entered the analysis as
7
8 controls. This study was approved by the Human Research Ethics Committee of Changzheng Hospital
9
10 (2017SL046), and informed consent was obtained from all participants.
11
12

13 14 **Patient and Public Involvement**

15
16 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of
17
18 our research.
19
20
21

22 **Demographic and clinical characteristics**

23
24 Demographic variables included gender, age, occupation, education level, income, quarantine status, and
25
26 marital status. Clinical variables included clinical diagnosis, disease duration, patient global assessment
27
28 visual analogue scale (PGA-VAS) score, sleep quality and disorders, weekly exercise frequency, and
29
30 subjective perception of the COVID-19 epidemic. Subjective perception of the COVID-19 epidemic was
31
32 assessed via the following three questions: 1) “How dangerous is COVID-19 to life and health?”; 2)
33
34 “How much does COVID-19 affect life, work or study?”; and 3) “How confident are you in defeating
35
36 COVID-19?”. Responses were given on a five-point Likert scale from 1 (nothing at all) to 5 (highest).¹⁸
37
38
39
40
41
42

43 **Measurement of PTSD**

44
45 The PTSD checklist for DSM-5 (PCL-5) was used to assess PTSD symptoms.¹⁹ There are 20 items
46
47 including 4 symptom clusters: intrusion symptoms (Criterion B, items 1-5), avoidance symptoms
48
49 (Criterion C, items 6, 7), negative alterations in cognition or emotional symptoms (Criterion D, items 8-
50
51 14), and hyper-arousal symptoms (Criterion E, items 15-20). Each item was scored on a five-point Likert
52
53 scale from 0 (nothing at all) to 4 (extremely), representing the degree to which an individual has been
54
55 bothered by PTSD-related symptoms during the past month. The overall score and the sum of each
56
57
58
59
60

1
2
3
4 symptom were both investigated. A score of 33 or greater was suggested as a probable diagnosis of PTSD.

5
6 The Chinese version of the PCL-5 has psychometric properties that are similar to those of the original
7
8
9 version and is widely used in trauma-related research and practice.²⁰ The COVID-19 epidemic put the
10
11 Chinese population at risk of a deadly pandemic. According to PCL-5's DSM-5 Life Events List (LEC-
12
13 5),²¹ this public health disaster is a traumatic event. Therefore, PCL-5 was used to assess PTSD symptoms.

14 15 16 17 **Measurement of sleep quality**

18
19 Self-reported sleep quality was measured based on 4 questions extracted from the Pittsburgh Sleep
20
21 Quality Index (PSQI),²² including “subjective sleep quality”, “unable to fall asleep within 30 minutes”,
22
23 “easily waking up at night or in the early morning” and “sleep time lasting for one month”. Each item
24
25 was scored from 0 to 3, with higher scores indicating more severe sleep disorders.
26
27
28

29 30 **Statistical Analysis**

31
32 Statistical analysis was performed using IBM SPSS version 21.0. A two-tailed test was used, and $p < 0.05$
33
34 was considered as statistically significant. Descriptive and frequency statistics (mean, [SD] and
35
36 percentages) were used to describe baseline demographic information and clinical information. First,
37
38 descriptive statistics were calculated for the demographic variables, clinical diagnosis data, disease
39
40 duration data, and subjective evaluation scores of the RD patient population. The differences in the PTSD
41
42 symptoms and sleep quality between the two groups were examined. If the data met normality, t-test was
43
44 used; otherwise, Mann-Whitney U test was used. Logistic regression analysis was used to estimate the
45
46 odds of experiencing PTSD symptoms among patients with RD compared to healthy people. Last,
47
48 hierarchical regression analysis was used to determine the independent variables related to PTSD in the
49
50 RD group.
51
52
53
54
55
56
57
58
59
60

Results

Demographic and clinical information of the RD patients

A total of 490 RD patients were recruited to complete the survey. Of the 490 respondents, 4 participants were removed due to illogical answers (for example, all choices were one or zero). Therefore, 486 participants were included in this analysis. As illustrated in Table 1, the sample comprised 301 males and 185 females with an average age of 40.03 years (SD, 14.70 years). Regarding the diagnosis, there were 289 (59.5%) patients with AS, 79 (16.3%) patients with RA, 15 (3.1%) patients with SLE, 10 (2.1%) patients with osteoarthritis (OA), 10 (2.1%) patients with osteoporosis (OP), 33 (6.8%) patients with gout, 10 (2.1%) patients with Sjogren's syndrome (SS), 11 (2.3%) patients with psoriatic arthritis (PsA) and 33 (6.8%) with other rheumatic diseases. In terms of the classification of the course of their RD, 39 (8.0%) patients were diagnosed less than 1 year ago, 205 (42.2%) patients were diagnosed between 1 and 5 years ago, and 242 (49.8%) patients were diagnosed more than 5 years ago. A total of 292 (60.1%) patients had PGA-VAS scores between 1 and 5, and 194 (39.9%) patients had PGA-VAS scores between 6 and 10. The subjective perception of the COVID-19 epidemic scores (1-5) were as follows: Q1 (2.52±1.18), Q2 (3.26±1.10), and Q3 (4.38±0.81).

The difference of PTSD symptoms and sleep quality between RD patients and healthy controls

The PTSD symptoms and sleep quality of two groups were then analysed (Table 2). The mean PCL-5 score of the patients with RD (18.40 ± 11.47) was significantly higher than that of the healthy controls (11.07 ± 10.04) ($p < 0.001$), with all four criteria rated significantly higher for RD patients than healthy respondents ($p < 0.001$), indicating that all four types of symptoms (intrusion, avoidance, negative changes in cognition or mood, hyper-arousal) are more severe in rheumatic patients. A total of 12.1% (59/486) of RD patients and 4.1% (20/486) of healthy controls scored 33 or higher and met the diagnostic

1
2
3
4 criteria for PTSD. Compared with the number of healthy controls, there were significantly more RD
5
6 patients who fulfilled the diagnostic criteria for PTSD ($p<0.001$). Logistic regression analysis showed
7
8 that the unadjusted OR of experiencing PTSD symptoms among patients with RD compared to
9
10 healthy people was 3.12 (95%CI 1.86-5.21), and the adjusted OR value was 3.26 (95%CI 1.94-5.48)
11
12 after controlling for gender and age.
13
14

15
16
17 In terms of the diagnostic classification, although there were no significant differences between the
18
19 subgroups, the Criterion B (intrusion symptoms) scores of the SLE patients were significantly higher
20
21 than those of the RA patients ($p<0.05$) (see Figure 1).
22
23

24
25 Regarding sleep quality and disorders, the scores of the four items from the PSQI (“subjective sleep
26
27 quality”, “unable to fall asleep within 30 minutes”, “easily waking up at night or in the early morning”
28
29 and “sleep time”) were significantly higher in the RD patients than the healthy control group. The results
30
31 indicated that during the COVID-19 pandemic, the prevalence and severity of PTSD were significantly
32
33 higher in RD patients than healthy controls, and the sleep quality of PD patients was also worse.
34
35
36

37 **Factors related to PTSD in RD patients**

38
39
40 With the PCL-5 score as the dependent variable and related variables as independent variables, the results
41
42 of the hierarchical regression analysis were listed in Table 3.
43
44

45
46 In the first step, the demographic variables included accounted for 2.3% of the variance in PTSD
47
48 symptoms. In the second step, the clinical characteristics of the RD patients were included in the model,
49
50 and the subjective assessment of the disease had a significant effect on the PCL-5 scores. For the course
51
52 of the RD, we defined “1-5 years” as a dummy variable and found that the PCL-5 scores in the “<1 year”
53
54 group were significantly higher than those in the reference group ($p<0.05$) (see Figure 2). These features
55
56 related to RD accounted for 5.8% of the unique variance. In the third step, two questions on the subjective
57
58
59
60

1
2
3
4 perception of the COVID-19 epidemic (Q2 and Q3) were also statistically significant ($p < 0.001$),
5
6 accounting for 7.9% of the difference in the results. The sleep quality score was added to the final step
7
8 of the hierarchical regression, thereby increasing the variance by 5.8%.

9
10
11 In the final model, gender ($\beta = 0.147$, $p = 0.001$), subjective assessment of the disease ($\beta = 0.112$, $p = 0.014$),
12
13 and Q2 regarding the subjective perception of the COVID-19 epidemic ($\beta = 0.110$, $p = 0.046$) were
14
15 positively correlated with the severity of PTSD symptoms, whereas age ($\beta = -0.155$, $p = 0.001$) and Q3 ($\beta = -$
16
17 0.194 , $p < 0.001$) were negatively correlated with PTSD symptoms. In summary, the total variation
18
19 contribution of these variables to the PCL-5 score was significant ($R^2 = 21.7\%$, $F = 10.899$, $p < 0.001$).
20
21
22
23
24
25
26
27

28 Discussion

29
30 Although the disease status and the treatment of RD patients have been widespread concerned,²³ almost
31
32 nothing is known with certainty about the psychological impact of the COVID-19 pandemic on RD
33
34 patients. In fact, RD patients were more susceptible to mental disorders during this COVID-19 outbreak.

35
36 It was demonstrated that RD patients suffered more from PTSD and sleep disorders than healthy controls
37
38 and had significantly higher PCL-5 scores and individual criteria scores. That is to say, RD patients have
39
40 higher odds of developing PTSD in the context of the COVID-19 pandemic. Our findings confirm the
41
42 importance of psychological assessment and care for RD patients during the pandemic.
43
44
45
46
47

48 Fears had risen in RD patients because of the higher risks of COVID-19 infection, as a result of high
49
50 similarity in clinical symptoms between RDs and COVID-19.¹³ A significant bidirectional relationship
51
52 between autoimmune diseases and PTSD was observed.²⁴ That is, PTSD patients were prone to
53
54 comorbidity with autoimmune disease,²⁵ and vice versa.²⁶ It was hypothesised that psychoneuroimmunity
55
56 (PNI) imbalance was the behind reason. PTSD was characterized by abnormal activation of the
57
58
59
60

1
2
3
4 hypothalamus-pituitary-adrenal axis (HPA axis), which was thought to communicate with the immune
5
6 system in a two-way manner.²⁷ On the one hand, it had been suggested that dysregulation of the HPA
7
8 axis will exacerbate systemic inflammation, which may be involved in the pathogenesis of chronic
9
10 inflammatory autoimmune diseases such as SLE and RA.²⁸ On the other hand, the chronic inflammatory
11
12 state caused by RD will aggravate the dysregulation of the HPA axis, which will further disturb the
13
14 physiological stress response of RD patients and make them more susceptible to PTSD.¹¹ Circulating
15
16 cytokines may also be involved in making RD patients more susceptible to PTSD. Some recent reports
17
18 demonstrated that serum interleukin-1 (IL-1), IL-6, tumour necrosis factor (TNF) and interferon (IFN)-
19
20 γ levels were increased in patients with PTSD.²⁹ These factors were also involved in the pathogenesis of
21
22 RDs, such as RA and SLE.³⁰

23
24
25
26
27
28
29
30 As expected, the sleep of RD patients was disturbed, in accordance with the results of previous studies.³¹
31
32 Psychosocial variables, steroid use, and chronic pain were possible psychobiological factors.³² Sleep
33
34 disorders also seemed to be a core feature of PTSD,³³ suggesting that PTSD symptoms may be worse in
35
36 RD patients.
37
38

39
40 Although no significant difference was observed in the PCL-5 scores among different diagnosis
41
42 subgroups, all standard scores of patients with SLE and OP tended to be higher. SLE patients may be
43
44 more stressed due to severe systemic involvement and drug shortages. They were concerned that
45
46 chloroquine will become a specific drug for COVID-19,³⁴ resulting in a higher Criterion B (intrusion
47
48 symptom) score for SLE patients than for other RA patients. Consistent with previous findings, patients
49
50 with OP may be more sensitive to PTSD due to age.³⁵ However, future studies with more samples should
51
52 be carried out to verify and expand such results.
53
54
55
56

57
58 It is not lightweight to explore the psychological impact of COVID-19 in different groups of RD patients.
59
60

1
2
3
4 Consequently, female, old age, poor sleep quality, long duration of RD, poor subjective evaluation of the
5
6 disease and a pessimistic subjective perception of the epidemic were identified as risk factors for PTSD
7
8
9 in RD patients during the COVID-19 epidemic.

10
11 In the current study, females were at higher risk to develop PTSD, in line with previous studies that
12
13 explored predictors of PTSD during the COVID-19 epidemic.^{15 36} It has been shown that females usually
14
15 tended to present depression, physical anxiety sensitivity, and helplessness which were all proven to be
16
17 PTSD-related risk factors.³⁷ As expected, age and sleep quality were predictive factors of PTSD and have
18
19
20
21
22 been widely explored in relevant studies.^{38 39}

23
24 It is important to note that long duration and poor subjective assessment of RD determined the risk of
25
26 PTSD to a certain extent. Patients with longer disease course were more likely to suffer from
27
28 psychological problems caused by chronic stress.⁴⁰ Among people with different disease durations, those
29
30 in “1-5 years” group had significantly higher PTSD levels than those in “<1 year” group. However,
31
32
33
34 inconsistent with the hypothesis, the difference between the “1-5 years” and “>5 years” group was not
35
36
37 significant. One possible reason is that patients who were diagnosed as more than 5 year ago have adapted
38
39 to their disease and have even become more resilient to other health-related stressors. Chronic pain
40
41 usually determined the subjective assessment of the disease in RD patients, which was usually
42
43 complicated by PTSD.⁴¹ Obviously, during the pandemic of a life-threatening infectious disease, patients
44
45
46 with a long disease duration and chronic pain should be regarded as at risk of PTSD.
47
48

49
50 Regarding the subjective perception of the epidemic, the symptoms of PTSD caused by pessimism and
51
52 fear were more severe, which was consistent with research on the psychological impact of SARS.¹⁸
53
54
55 Media reports emphasized that COVID-19 was a unique threat, which further exacerbated the possibility
56
57
58 of panic, stress hysteria and fear. Fear is an adaptive response that triggers defensive behaviours to protect
59
60

1
2
3
4 ourselves. If the fear is not managed properly, PTSD will develop.⁴² Thus, applying psychological
5
6 interventions to reduce pandemic fears and instilling emotional adaptability during the COVID-19
7
8 pandemic may help prevent the development of PTSD.
9

10
11 Currently, several limitations are worth considering. This study lacked evidences on the prevalence of
12
13 PTSD before the epidemic in both RD patients and health individuals. As a result, it is difficult to
14
15 determine whether the high prevalence of PTSD in the RD group is due to COVID-19. Furthermore,
16
17 our findings rely on a self-reported survey which may question the authenticity of response as well as
18
19 give consideration to social desirability bias, which refers to the tendency for survey respondents to
20
21 over-endorse items that they perceive others judge favourably. If participants believe that it is socially
22
23 desirable to have psychological problems during the COVID-19 pandemic in order to get more
24
25 attention, some who do not follow guidance may be reluctant to respond truthfully. Thus, the results
26
27 may be inflated. Lastly, to guarantee a reliable subgroup analysis, larger samples are warranted in the
28
29 future.
30
31
32
33
34
35
36
37

38 **Conclusion**

39
40 In the context of COVID-19, the present study will provide references not only rheumatologically but
41
42 also psychologically. It is suggested that, compared to healthy controls, RD patients present a higher
43
44 prevalence and severity of PTSD and more sleep disturbances. Under such future life-threatening
45
46 infectious epidemics, as regular clinical care, the importance of mental health in RD patients is nothing
47
48 to sneeze at.
49
50
51

52 **Contributorship statement**

53
54 XW, XG, ZS contributed to the writing of this article and the statistical analysis of this article, who
55
56 are co-first authors, HM, WL and HX led the whole study, including putting forward this study,
57
58
59
60

1
2
3
4 carrying out the study, and was the co-corresponding author. ZW and HL contributed to perform
5
6 the investigation and collection of all data and part of the statistical analysis of this article.
7
8
9

10 11 **Competing interests**

12
13
14 The authors declare that they have no conflicts of interest.
15
16

17 18 **Funding**

19
20 This work was supported by grants from the National Natural Science Foundation of China (31770988
21
22 to X.W., 32071086 to W.L., and 31821003 to H.X.); China Ministry of Science and Technology
23
24 (2018AAA0100300 to H.X.). Shanghai Municipal Key Clinical Specialty Fund (shslczdzk02602 to
25
26 H.X.). The funders of the study had no role in study design, data collection, data analysis, data
27
28 interpretation, or writing of the report.
29
30
31
32
33
34
35
36
37

38 39 **Data sharing statement**

40 Data can be provided after the Article is published through the email address of the corresponding authors
41
42 for communication. The corresponding authors have the right to decide whether to share the data or not
43
44 based on the research objectives and plan provided. With the permission of the corresponding authors,
45
46 we can provide participant data without names and identifiers.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

	RD patients	
	N	%
Age		
18-34	223	45.9
35-60	203	41.8
>60	60	12.3
Gender		
Male	301	61.9
Female	185	38.1
Clinical diagnosis		
Rheumatoid arthritis, RA	79	16.3
Ankylosing spondylitis, AS	289	59.5
Systemic lupus erythematosus, SLE	15	3.1
Osteoarthritis, OA	10	2.1
Osteoporosis, OP	10	2.1
Gout	33	6.8
Sjogren's syndrome, SS	10	2.1
Psoriatic arthritis, PsA	11	2.3
Other	29	6.0
Duration of disease		
<1 year	39	8.0

1-5 years	205	42.2
>5 years	242	49.8
PGA-VAS scores		
1-5	292	60.1
6-10	194	39.9
Perception of the COVID-19 epidemic situation	MEAN	SD
Q1: How dangerous is COVID-19 to life and health?	2.52	1.18
Q2: How much does COVID-19 affect life, work or study?	3.26	1.10
Q3: How confident are you in defeating COVID-19?	4.38	0.81

Table 1: Demographic information and clinical information for all the RD patients

Note: RD=rheumatic diseases. PGA-VAS scores=Patient Global Assessment Visual Analogue Scale scores.

	RD patients		Control		Chi-square/t	p-value
	Mean/N	SD/%	Mean/N	SD/%		
Total	486	100.00	486	100.00		
Age						
18-34	223	45.90	213	43.88	3.418	0.181
35-60	203	41.80	227	46.71		
>60	60	12.30	46	9.50		
Gender						
Male	301	61.90	302	62.14	0.004	0.947
Female	185	38.10	184	37.90		
PCL-5 Scores						
Total scores	18.40	11.47	11.07	10.00	-10.601	<0.001

1							
2							
3							
4							
5	Criterion B	4.86	3.40	3.22	3.34	-7.577	<0.001
6							
7							
8	Criterion C	2.21	1.97	0.89	1.43	-11.978	<0.001
9							
10							
11	Criterion D	6.20	4.59	3.58	3.94	-7.617	<0.001
12							
13							
14	Criterion E	5.12	3.66	3.58	3.44	-10.601	<0.001
15							
16	Sleep quality						
17							
18	Subjective sleep quality	1.19	0.77	0.78	0.70	-8.424	<0.001
19							
20							
21	Difficulty falling asleep	1.07	1.09	0.51	0.88	-8.782	<0.001
22							
23							
24	Frequent nocturnal or early morning awakening	1.41	1.16	0.82	1.00	-8.269	<0.001
25							
26							
27	Sleep duration	0.95	0.85	0.77	0.83	-3.217	0.001
28							

Table 2: Group differences in demographic information, PCL-5 scores and sleep quality between the RD patient group and the control group

Note: RD=rheumatic diseases. PCL-5=PTSD checklist for DSM-5.

Variables	PCL-5 score				R Square	R Square Change	F	p-value
	B	β	t	p-value				
Step 1								
Age	-0.064	-0.081	-1.762	0.079	0.023	0.023	5.576	0.004
Female vs. Male	3.452	0.146	3.166	0.002				
Step 2								
Age	-0.100	-0.127	-2.719	0.007	0.080	0.058	8.381	<0.001
Female vs. Male	4.253	0.180	3.940	0.000				
Duration of disease <1 year vs. 1-5 years	-4.339	-0.103	-2.243	0.025				
Duration of disease >5 years vs. 1-5 years	0.170	0.007	0.156	0.876				
PGA-VAS scores	1.055	0.210	4.612	<0.001				

Step 3

1									
2									
3									
4									
5									
6	Age	-0.088	-0.112	-2.491	0.013	0.159	0.079	11.260	<0.001
7									
8	Female vs. Male	3.797	0.161	3.579	<0.001				
9									
10									
11	Duration of disease <1 year vs. 1-5 years	-3.847	-0.091	-2.061	0.040				
12									
13	Duration of disease >5 years vs. 1-5 years	0.182	0.008	0.174	0.862				
14									
15									
16	PGA-VAS scores	0.905	0.180	4.014	<0.001				
17									
18	Q1: How dangerous is COVID-19 to life and health?	0.457	0.047	0.964	0.336				
19									
20	Q2: How much does COVID-19 affect life, work or study?	1.816	0.175	3.544	<0.001				
21									
22	Q3: How confident are you in defeating COVID-19?	-3.086	-0.217	-4.970	<0.001				
23									
24									
25									
26									
27	Step 4								
28									
29	Age	-0.121	-0.155	-3.412	0.001	0.217	0.058	10.899	<0.001
30									
31	Female vs. Male	3.471	0.147	3.323	0.001				
32									
33									
34	Duration of disease <1 year vs. 1-5 years	-2.351	-0.056	-1.286	0.199				
35									
36									
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									

Duration of disease >5 years vs. 1-5 years	0.556	0.024	0.546	0.586
PGA-VAS scores	0.561	0.112	2.473	0.014
Q1: How dangerous is COVID-19 to life and health?	0.520	0.053	1.130	0.259
Q2: How much does COVID-19 affect life, work or study?	1.331	0.128	2.642	0.009
Q3: How confident are you in defeating COVID-19?	-2.754	-0.194	-4.545	<0.001
Subjective sleep quality	1.627	0.110	1.999	0.046
Difficulty falling asleep	0.954	0.090	1.678	0.094
Frequent nocturnal or early morning awakening	0.715	0.072	1.401	0.162
Sleep duration	0.878	0.065	1.371	0.171

Table 3: Regression analyses with the PCL-5 score as the dependent variable in all RD patients (n=486)

Note: B =unstandardized beta; β =standardized regression weight. The duration of disease was transformed into two dummy variables (<1 year vs. 1-5 years, >5 years vs. 1-5 years), with 1-5 years as the reference group.

Figure legends

Figure 1: Group differences in all the PCL-5 criteria between the different subgroups of RD

Note: * p-value<0.05. PCL-5=PTSD checklist for DSM-5. All 4 criteria (B, C, D, E) are components of the PCL-5.

Figure 2: Differences in the PCL-5 scores between different disease duration groups

Note: * p-value<0.05. The duration of disease was transformed into three groups (< 1 year, 1-5 years, > 5 years).


References


1. SK B, RK W, LE S, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet (London, England)* 2020;395(10227):912-20. doi: 10.1016/s0140-6736(20)30460-8
2. F D, L M, V N. PTSD as the second tsunami of the SARS-Cov2 pandemic. *Psychological medicine* 2020:1-6. doi: 10.1017/s0033291720001336
3. KK W, SK C, TM M. Posttraumatic stress after SARS. *Emerging infectious diseases* 2005;11(8):1297-300. doi: 10.3201/eid1108.041083
4. SM L, WS K, AR C, et al. Psychological impact of the 2015 MERS outbreak on hospital workers and quarantined hemodialysis patients. *Comprehensive psychiatry* 2018;87:123-27. doi: 10.1016/j.comppsy.2018.10.003
5. S R. Ebola's mental-health wounds linger in Africa. *Nature* 2015;519(7541):13-4. doi: 10.1038/519013a
6. Benfante A, Di Tella M, Romeo A, et al. Traumatic Stress in Healthcare Workers During COVID-19 Pandemic: A Review of the Immediate Impact. *Frontiers in psychology* 2020;11:569935. doi: 10.3389/fpsyg.2020.569935
7. Li Y, Scherer N, Felix L, et al. Prevalence of depression, anxiety and post-traumatic stress disorder in health care workers during the COVID-19 pandemic: A systematic review and meta-analysis. *PLoS one* 2021;16(3):e0246454. doi: 10.1371/journal.pone.0246454
8. TM L, I C, LW C, et al. Ageing and psychological response during the post-SARS period. *Aging & mental health* 2006;10(3):303-11. doi: 10.1080/13607860600638545

- 1
2
3 9. Sun L, Sun Z, Wu L, et al. Prevalence and risk factors for acute posttraumatic stress
4 disorder during the COVID-19 outbreak. *Journal of affective disorders*
5 2021;283:123-29. doi: 10.1016/j.jad.2021.01.050
- 6
7 10. Abdalla S, Ettman C, Cohen G, et al. Mental health consequences of COVID-19: a
8 nationally representative cross-sectional study of pandemic-related stressors
9 and anxiety disorders in the USA. *BMJ open* 2021;11(8):e044125. doi:
10 10.1136/bmjopen-2020-044125
- 11
12 11. SJ dB, FW K, FC S, et al. Experimental stress in inflammatory rheumatic diseases: a
13 review of psychophysiological stress responses. *Arthritis research & therapy*
14 2010;12(3):R89. doi: 10.1186/ar3016
- 15
16 12. Larice S, Ghiggia A, Di Tella M, et al. Pain appraisal and quality of life in 108
17 outpatients with rheumatoid arthritis. *Scandinavian journal of psychology*
18 2020;61(2):271-80. doi: 10.1111/sjop.12592
- 19
20 13. Zhong J, Shen G, Yang H, et al. COVID-19 in patients with rheumatic disease in
21 Hubei province, China: a multicentre retrospective observational study. *The*
22 *Lancet Rheumatology* 2020;2(9):e557-e64. doi: 10.1016/s2665-
23 9913(20)30227-7
- 24
25 14. DP M, V A, AY G, et al. Rheumatologists' perspective on coronavirus disease 19
26 (COVID-19) and potential therapeutic targets. *Clinical rheumatology* 2020 doi:
27 10.1007/s10067-020-05073-9
- 28
29 15. N L, F Z, C W, et al. Prevalence and predictors of PTSS during COVID-19 outbreak
30 in China hardest-hit areas: Gender differences matter. *Psychiatry research*
31 2020;287:112921. doi: 10.1016/j.psychres.2020.112921
- 32
33 16. Liew J, Lucas Williams J, Dobscha S, et al. Posttraumatic stress disorder and
34 correlates of disease activity among veterans with ankylosing spondylitis.
35 *Rheumatology international* 2017;37(10):1765-69. doi: 10.1007/s00296-017-
36 3801-7
- 37
38 17. Mikuls T, Padala P, Sayles H, et al. Prospective study of posttraumatic stress
39 disorder and disease activity outcomes in US veterans with rheumatoid
40 arthritis. *Arthritis care & research* 2013;65(2):227-34. doi: 10.1002/acr.21778
- 41
42 18. P W, Y F, Z G, et al. The psychological impact of the SARS epidemic on hospital
43 employees in China: exposure, risk perception, and altruistic acceptance of risk.
44 *Canadian journal of psychiatry Revue canadienne de psychiatrie*
45 2009;54(5):302-11. doi: 10.1177/070674370905400504
- 46
47 19. CA B, FW W, MT D, et al. The Posttraumatic Stress Disorder Checklist for DSM-5
48 (PCL-5): Development and Initial Psychometric Evaluation. *Journal of traumatic*
49 *stress* 2015;28(6):489-98. doi: 10.1002/jts.22059
- 50
51 20. P L, L W, C C, et al. The underlying dimensions of DSM-5 posttraumatic stress
52 disorder symptoms in an epidemiological sample of Chinese earthquake
53 survivors. *Journal of anxiety disorders* 2014;28(4):345-51. doi:
54 10.1016/j.janxdis.2014.03.008
- 55
56 21. FW W, BT L, TM K, et al. The PTSD Checklist for DSM-5 (PCL-5) – LEC-5 and Extended
57 Criterion A [Measurement instrument].
- 58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- https://www.ptsd.va.gov/professional/assessment/documents/PCL-5_LEC_criterionA.pdf. 2013 [accessed January 2 2021].
22. T M, P T, K B, et al. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis. *Sleep medicine reviews* 2016;25:52-73. doi: 10.1016/j.smrv.2015.01.009
23. RB L, PM M, F K, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. *Annals of the rheumatic diseases* 2020;79(7):851-58. doi: 10.1136/annrheumdis-2020-217877
24. JA S, KM N, KC K, et al. Posttraumatic Stress Disorder and Inflammation: Untangling Issues of Bidirectionality. *Biological psychiatry* 2020;87(10):885-97. doi: 10.1016/j.biopsych.2019.11.005
25. Benros M. Posttraumatic stress disorder and autoimmune diseases. *Biological psychiatry* 2015;77(4):312-3. doi: 10.1016/j.biopsych.2014.12.006
26. H S, F F, G T, et al. Association of Stress-Related Disorders With Subsequent Autoimmune Disease. *JAMA* 2018;319(23):2388-400. doi: 10.1001/jama.2018.7028
27. Somvanshi PR, Mellon SH, Yehuda R, et al. Role of enhanced glucocorticoid receptor sensitivity in inflammation in PTSD: Insights from computational model for circadian-neuroendocrine-immune interactions. *Am J Physiol Endocrinol Metab* 2020 doi: 10.1152/ajpendo.00398.2019 [doi] [published Online First: 2020/04/22]
28. AW E, EW V, H vM, et al. Does stress affect the joints? Daily stressors, stress vulnerability, immune and HPA axis activity, and short-term disease and symptom fluctuations in rheumatoid arthritis. *Annals of the rheumatic diseases* 2014;73(9):1683-8. doi: 10.1136/annrheumdis-2012-203143
29. IC P, MP V-M, LG C, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. *The lancet Psychiatry* 2015;2(11):1002-12. doi: 10.1016/s2215-0366(15)00309-0
30. Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. *Autoimmunity reviews* 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003
31. Kim J, Park E, Lee K, et al. Association of sleep duration with rheumatoid arthritis in Korean adults: analysis of seven years of aggregated data from the Korea National Health and Nutrition Examination Survey (KNHANES). *BMJ open* 2016;6(12):e011420. doi: 10.1136/bmjopen-2016-011420
32. SR S, CM T, DP DC. Autoimmune rheumatic disease and sleep: a review. *Current opinion in pulmonary medicine* 2015;21(6):553-6. doi: 10.1097/mcp.0000000000000215
33. VI S, P M. Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature? *Sleep medicine reviews* 2008;12(3):169-84. doi: 10.1016/j.smrv.2007.08.008

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
34. CA P. Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic. *The Journal of rheumatology* 2020;47(6):787-90. doi: 10.3899/jrheum.200395
 35. JM C, V S. Trauma and Aging. *Current psychiatry reports* 2018;20(10):93. doi: 10.1007/s11920-018-0943-6
 36. Di Tella M, Romeo A, Benfante A, et al. Mental health of healthcare workers during the COVID-19 pandemic in Italy. *Journal of evaluation in clinical practice* 2020;26(6):1583-87. doi: 10.1111/jep.13444
 37. Li S, Graham B. Why are women so vulnerable to anxiety, trauma-related and stress-related disorders? The potential role of sex hormones. *The lancet Psychiatry* 2017;4(1):73-82. doi: 10.1016/s2215-0366(16)30358-3
 38. JL S, K R, R E-G, et al. Associations between physical health conditions and posttraumatic stress disorder according to age. *Aging & mental health* 2019:1-9. doi: 10.1080/13607863.2019.1693969
 39. Richards A, Kanady J, Neylan T. Sleep disturbance in PTSD and other anxiety-related disorders: an updated review of clinical features, physiological characteristics, and psychological and neurobiological mechanisms. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2020;45(1):55-73. doi: 10.1038/s41386-019-0486-5
 40. LY M, MR M. Post-Traumatic Stress Disorder: The Relationship Between the Fear Response and Chronic Stress. *Chronic stress (Thousand Oaks, Calif)* 2017;1:2470547017713297. doi: 10.1177/2470547017713297
 41. S K, JD O. The Interaction Between Chronic Pain and PTSD. *Current pain and headache reports* 2019;23(12):91. doi: 10.1007/s11916-019-0828-3
 42. Morey R, Haswell C, Stjepanović D, et al. Neural correlates of conceptual-level fear generalization in posttraumatic stress disorder. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2020;45(8):1380-89. doi: 10.1038/s41386-020-0661-8





11-049749 on 30 March 2022. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Pg 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Pg 3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Pg 5
Objectives	3	State specific objectives, including any prespecified hypotheses	Pg 6
Methods			
Study design	4	Present key elements of study design early in the paper	Pg 6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pg 6
Participants	6	(a) <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Pg 6
		(b) <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Pg 6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Pg 7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pg 7-8
Bias	9	Describe any efforts to address potential sources of bias	Pg 6
Study size	10	Explain how the study size was arrived at	Pg 6

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Pg 8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Pg 8
		(b) Describe any methods used to examine subgroups and interactions	Pg 8
		(c) Explain how missing data were addressed	
		(d) <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	Pg 8
		(e) Describe any sensitivity analyses	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Pg 9
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Pg 9
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	Pg 9
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Results			
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Pg 10
		(b) Report category boundaries when continuous variables were categorized	Pg 10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Pg 10
Discussion			
Key results	18	Summarise key results with reference to study objectives	Pg 11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pg 14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Pg 14
Generalisability	21	Discuss the generalisability (external validity) of the study results	Pg 14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Pg 15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.